Clinical Pharmacokinetics and Selective Pharmacodynamics of New Angiotensin Converting Enzyme Inhibitors (original) (raw)

• Kelly JG, O’Malley K. Clinical pharmacokinetics of the newer ACE inhibitors: a review. Clin Pharmacokinet 1990; 19: 177–96
  Article PubMed CAS Google Scholar
• Kubo SH, Cody RJ. Clinical pharmacokinetics of the angiotensin converting enzyme inhibitors: a review. Clin Pharmacokinet 1985; 10: 377–91
  Article PubMed CAS Google Scholar
• Kaiser G, Ackermann R, Brechbuhler S, et al. Pharmacokinetics of the angiotensin-converting enzyme inhibitor, benazepril HCl (CGS 14824A), in healthy volunteers after single and repeated administration. Biopharm Drug Dispos 1989; 10: 365–76
  Article PubMed CAS Google Scholar
• Dieterle W, Ackermann R, Kaiser G. Pharmacokinetics of benazeprilat after intravenous administration in healthy volunteers [abstract]. Eur J Clin Pharmacol 1989; 9 Suppl.: A303
  Google Scholar
• Williams PEO, Brown AN, Rajaguru S, et al. The pharmacokinetics and bioavailability of cilazapril in normal man. Br J Clin Pharmacol 1989; 27: 181S–8S
  Article PubMed CAS Google Scholar
• Shionoiri H, Yasuda G, Ikeda A, et al. Pharmacokinetics and depressor effect of delapril in patients with essential hypertension. Clin Pharmacol Ther 1987; 41: 74–9
  Article PubMed CAS Google Scholar
• Onoyama K, Nanishi F, Okuda S, et al. Pharmacokinetics of a new angiotensin converting enzyme inhibitor (delapril) in patients with deteriorated kidney function and in normal control subjects. Clin Pharmacol Ther 1988; 43: 242–9
  Article PubMed CAS Google Scholar
• Singhvi SM, Duchin KL, Morrison RA, et al. Disposition of fosinopril sodium in healthy subjects. Br J Clin Pharmacol 1988; 25: 9–15
  Article PubMed CAS Google Scholar
• Ulm EH, Hichens M, Gomez HJ, et al. Enalapril maleate and a lysine analogue (MK521): disposition in man. Br J Clin Pharmacol 1982; 14: 357–62
  Article PubMed CAS Google Scholar
• Rakhit A, Hurley ME, Tipnis V, et al. Pharmacokinetics and pharmacodynamics of pentopril, a new angiotensin-converting-enzyme inhibitor in humans. J Clin Pharmacol 1986; 26: 156–64
  PubMed CAS Google Scholar
• Rakhit A, Kochak GM, Tipnis V, et al. Pharmacokinetics of pentopril in the elderly. Br J Clin Pharmacol 1987; 24: 351–7
  Article PubMed CAS Google Scholar
• Kochak GM, Rakhit A, Thompson TN, et al. Pentopril-cimetidine interaction caused by a reduction in hepatic blood flow. J Clin Pharmacol 1989; 28: 222–7
  Google Scholar
• Rakhit A, Radensky P, Szerlip HM, et al. Effect of renal impairment on disposition of pentopril and its active metabolite. Clin Pharmacol Ther 1988; 44: 39–48
  Article PubMed CAS Google Scholar
• Lees KR, Green ST, Reid JL. Influence of age on pharmacokinetics and pharmacodynamics of perindopril. Clin Pharmacol Ther 1988; 44: 418–25
  Article PubMed CAS Google Scholar
• Ferry JJ, Cetnarowski AB, Sedman AJ, et al. Multiple dose cimetidine administration does not influence the single-dose pharmacokinetics of quinapril and its active metabolite (CI-928). J Clin Pharmacol 1988; 28: 48–51
  PubMed CAS Google Scholar
• Neub M, Vollmer K, Anderson J, et al. Pharmacokinetics of the ACE-inhibitor quinapril in young and elderly volunteers [abstract]. Eur J Clin Pharmacol 1989; 36 Suppl.: A222
  Google Scholar
• Eckert HG, Badian MJ, Gantz D, et al. Pharmacokinetics and biotransformation of 2-(N-((S)-1-ethoxycarboxyl-3-phenylpropyl)-L-alanyl)-(1S, 3S, 5S)-2-azabicyclo (3.3.0) octane-3-carboxylic acid (Hoe 498) in rat, dog, and man. Arzneimittelforschung 1984; 34: 1435–47
  PubMed CAS Google Scholar
• Witte PU, Irmisch R, Hajdu P, et al. Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (Hoe 498) in healthy subjects. Eur J Clin Pharmacol 1984; 27: 577–81
  Article PubMed CAS Google Scholar
• Thuillez C, Richer C, Giudicelli JF. Pharmacokinetics, converting enzyme inhibition and peripheral arterial haemodynamics of ramipril in healthy volunteers. Am J Cardiol 1987; 59: 38D–44D
  Article PubMed CAS Google Scholar
• Meyer BH, Muller O, Badian M, et al. Pharmacokinetics of ramipril in the elderly. Am J Cardiol 1987; 59: 33D–7D
  Article PubMed CAS Google Scholar
• The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429–35
  Article Google Scholar
• Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303–10
  Article PubMed CAS Google Scholar
• The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293–302
  Article Google Scholar
• Garg G, Yusuf S, Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA 1995; 273: 1450–6
  Article PubMed CAS Google Scholar
• Hobbs RE. Results of the ATLAS Study. High or low doses of ACE inhibitors for heart failure? Cleve Clin J Med 1998; 65: 539–42
  PubMed CAS Google Scholar
• Gruppo Italiano per lo Studio della Sopravvivenza nell’infarcto Miocardico. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115–22
  Google Scholar
• The Fourth International Study of Infarct Survival (ISIS-4) Collaborative Group. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58 050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669–85
  Article Google Scholar
• Chinese Cardiac Study Collaborative Group. Oral captopril versus placebo among 13 634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet 1995; 345: 686–7
  Article Google Scholar
• Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N Engl J Med 1992; 327: 678–84
  Article PubMed CAS Google Scholar
• ACE Inhibitor Myocardial Infarction Collaborative Group. Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. Circulation 1998; 97: 2202–12
  Article Google Scholar
• Pfeffer MA, Braunwald E, Moye LA, et al., for the SAVE Investigators. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial. N Engl J Med 1992; 327: 669–77
  Article PubMed CAS Google Scholar
• The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 1993; 342: 821–8
  Google Scholar
• Kober L, Torp-Pedersen C, Carlsen JE, et al., Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 1995; 333: 1670–6
  Article PubMed CAS Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–62
  Article PubMed CAS Google Scholar
• Marre M, Chatellier G, Leblanc H, et al. Prevention of diabetic nephropathy with enalapril in normotensive diabetics with microalbuminuria. BMJ 1988; 297: 1092–5
  Article PubMed CAS Google Scholar
• The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 1997; 349: 1787–92
  Article Google Scholar
• Ravid M, Savin H, Jurtin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577–81
  PubMed CAS Google Scholar
• Rose M, McMahon FG. Some problems with antihypertensive drug studies in the context of the new guidelines. Am J Hypertens 1990; 3: 151–5
  PubMed CAS Google Scholar
• Goa KL, Wagstaff AJ. Losartan potassium: a review of its pharmacology, clinical efficacy, and tolerability in the management of hypertension. Drugs 1996; 51: 820–45
  Article PubMed CAS Google Scholar
• Ellis ML, Patterson JH. A new class of antihypertensive therapy: angiotensin II antagonists. Pharmacotherapy 1996; 16: 849–60
  PubMed CAS Google Scholar
• Reid IA. Vasoactive peptides. In: Katzung BG, editor. Basic and clinical pharmacology. 7th ed. Stamford (CT): Appleton and Lange, 1998: 287–91
  Google Scholar
• White CM. Pharmacologic, pharmacokinetic, and therapeutic differences among ACE inhibitors. Pharmacotherapy 1998; 18: 588–99
  PubMed CAS Google Scholar
• Edling O, Bao G, Feelisch M, et al. Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J Pharmacol Exp Ther 1995; 275: 854–63
  PubMed CAS Google Scholar
• Chevillard C, Brown NL, Mathieu MN, et al. Differential effects of oral trandolapril and enalapril on rat tissue angiotensin converting enzyme. Eur J Pharmacol 1988; 147: 23–8
  Article PubMed CAS Google Scholar
• Pinto YM, van Veldhuisen DJ, Tjon-Ka-Jie RT, et al. Dose-finding study of imidapril, a novel angiotensin converting enzyme inhibitor, in patients with stable chronic heart failure. Eur J Clin Pharmacol 1996; 50: 265–8
  Article PubMed CAS Google Scholar
• Delacretaz E, Nussberger J, Puchler K, et al. Value of different clinical and biochemical correlates to assess angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol 1994; 24: 479–85
  Article PubMed CAS Google Scholar
• Unger TH, Gohlke P, Paul M, et al. Tissue renin-angiotensin-systems: fact or fiction? J Cardiovasc Pharmacol 1991; 18 Suppl. 2: 20–5
  Google Scholar
• Hoogkamer JF, Kleinbloesem CH, Nokhodian A, et al. Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with chronic renal failure. Eur J Clin Pharmacol 1998; 54: 59–61
  Article PubMed CAS Google Scholar
• Delacretaz E, Nussberger J, Puchler K, et al. Value of different clinical and biochemical correlates to assess angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol 1994; 24(3): 479–85
  Article PubMed CAS Google Scholar
• Bardelay C, Mach E, Worcel M, et al. Angiotensin-converting enzyme in rat brain and extraneural tissues visualized by quantitative autoradiography using 3H-trandolaprilate. J Cardiovasc Pharmacol 1989; 14: 511–8
  Article PubMed CAS Google Scholar
• Sybertz EJ, Watkins RW, Ahn HS, et al. Pharmacologic, metabolic, and toxicologic profile of spirapril (SCH 33844), a new angiotensin converting inhibitor. J Cardiovasc Pharmacol 1987; 10 Suppl. 7: S105–8
  Article PubMed CAS Google Scholar
• Friehe H, Ney P. Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. Arzneimittelforschung 1997; 47(2): 132–44
  PubMed CAS Google Scholar
• Wiseman LR, McTavish D. Trandolapril: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in essential hypertension. Drugs 1994; 48: 71–90
  Article PubMed CAS Google Scholar
• Arner P, Wade A, Engfeldt P, et al. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2mg to young and elderly patients with mild-to-moderate hypertension. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: S44–9
  PubMed Google Scholar
• Brown NL, Batel M-Y, Benzoni F, et al. Angiotensin-converting enzyme inhibition, anti-hypertensive activity and hemodynamic profile of trandolapril (RU 44570). Eur J Pharmacol 1988; 148: 79–91
  Article PubMed CAS Google Scholar
• Lenfant B, Mouren M, Bryce T, et al. Trandolapril: pharmacokinetics of single oral doses in healthy male volunteers. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: S38–43
  PubMed CAS Google Scholar
• Danielson B, Querin S, LaRochelle P, et al. Pharmacokinetics and pharmacodynamics of trandolapril after repeated administration of 2mg to patients with chronic renal failure and healthy control subjects. J Cardiovasc Pharmacol 1994; 23 Suppl. 4: S50–9
  PubMed Google Scholar
• Stimpel M, Bonn R, Koch B, et al. Pharmacology and clinical use of the new ACE-inhibitor moexipril. Cardiovascular Drug Reviews 1995; 13: 211–29
  Article CAS Google Scholar
• Stimpel M, Cawello W. Pharmacokinetics and ACE-inhibition of the new ACE-inhibitor moexipril: is coadministration with food of clinical relevance? [abstract]. Hypertension 1995; 25: 1384
  Google Scholar
• Grass P, Gerbeau C, Kutz K. Spirapril: pharmacokinetic properties and drug interactions. Blood Press 1994; 3 Suppl. 2: 7–13
  Article Google Scholar
• Stein G, Sierakowski B, Grass P, et al. Pharmacokinetics of spirapril and spiraprilat in patients with chronic renal failure. Blood Press 1994; 3 Suppl. 2: 47–53
  Article Google Scholar
• Hayduk K, Kraul H. Efficacy and safety of spirapril in mild-to-moderate hypertension. J Cardiovasc Pharmacol 1999; 34 Suppl. 1: S19–23
  Article PubMed CAS Google Scholar
• Puchler K, Sierakowski B, Roots I. Single dose and steady state pharmacokinetics of temocapril and temocaprilat in young and elderly hypertensive patients. Br J Clin Pharmacol 1998; 46: 363–7
  Article PubMed CAS Google Scholar
• Harder S, Thurmann PA, Ungethum W. Single dose and steady state pharmacokinetics and pharmacodynamics of the ACE-inhibitor imidapril in hypertensive patients. Br J Clin Pharmacol 1998; 45: 377–80
  Article PubMed CAS Google Scholar
• Meyer BH, Muller FO, Badenhorst PN, et al. Multiple doses of trandolapril do not affect warfarin pharmacodynamics. S Afr Med J 1995; 85: 768–70
  PubMed CAS Google Scholar
• Pritchard G, Lyons D, Webster J, et al. Indomethacin does not attenuate the hypotensive effect of trandolapril. J Hum Hypertens 1996; 10: 763–7
  PubMed CAS Google Scholar
• Hutt V, Michaelis K, Verbesselt R, et al. Lack of a pharmacokinetic interaction between moexipril and hydrochlorothiazide. Eur J Clin Pharmacol 1996; 51: 339–44
  Article PubMed CAS Google Scholar
• Van Hecken A, Verbesselt R, Depre M, et al. Moexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin. Eur J Clin Pharmacol 1993; 45: 291–3
  Article PubMed Google Scholar
• Drugdex ®. Spirapril Drugdex Drug Evaluation. Colorado: Micromedex, Sep 2001.
  Google Scholar
• Johnson BF, Wilson J, Johnson J, et al. Digoxin pharmacokinetics and spirapril, a new ACE inhibitor. J Clin Pharmacol 1991; 31: 527–30
  PubMed CAS Google Scholar
• Sierakowski B, Puchler K, Witte PU, et al. Single-dose pharmacokinetics of temocapril and temocapril diacid in subjects with varying degrees of renal impairment. Eur J Clin Pharmacol 1997; 53: 215–20
  Article PubMed CAS Google Scholar
• Puchler K, Eckl KM, Fritsche L, et al. Pharmacokinetics of temocapril and temocaprilat after 14 once-daily oral doses of temocapril in hypertensive patients with varying degrees of renal impairment. Br J Clin Pharmacol 1997; 44: 531–6
  Article PubMed CAS Google Scholar
• Suzuki H, Kawaratani T, Shioya H, et al. Study on pharmacokinetics of a new biliary excreted oral angiotensin converting enzyme inhibitor, temocapril (CS-622) in humans. Biopharm Drug Dispos 1993; 14: 41–50
  Article PubMed CAS Google Scholar
• Shionoiri H, Naruse M, Minamisawa K, et al. Fosinopril: clinical pharmacokinetics and clinical potential. Clin Pharmacokinet 1997; 32: 460–80
  Article PubMed CAS Google Scholar
• Hoogkamer JF, Kleinbloesem CH, Nokhodian A, et al. Pharmacokinetics of imidapril and its active metabolite imidaprilat following single dose and during steady state in patients with impaired liver function. Eur J Clin Pharmacol 1997; 51: 489–91
  Article PubMed CAS Google Scholar
• Harder S, Thurmann PA. Pharmacokinetic and pharmacodynamic interaction trial after repeated oral doses of imidapril and digoxin in healthy volunteers. Br J Clin Pharmacol 1997; 43: 475–80
  Article PubMed CAS Google Scholar
• The Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med 1997; 157: 2413–46
  Article Google Scholar
• Hansson L, Lindholm LH, Niskanen L. Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611–6
  Article PubMed CAS Google Scholar
• Pitt B, Segal R, Martinez FA, et al., for ELITE Study Investigators. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly study, ELITE). Lancet 1997; 349: 747–52
  Article PubMed CAS Google Scholar
• White CM. Angiotensin-converting-enzyme inhibition in heart failure or after myocardial infarction. Am J Health Syst Pharm 2000; 57 Suppl. 11: S18–25
  PubMed CAS Google Scholar
• The Heart Outcomes Prevention Evaluation Study Investigators. Vitamin E supplementation and cardiovascular events in high-risk patients. N Engl J Med 2000; 342: 154–60
  Article Google Scholar
• Manley HJ. Role of angiotensin-converting-enzyme inhibition in patients with renal disease. Am J Health-Syst Pharm 2000; 57 Suppl. 1: S12–8
  PubMed CAS Google Scholar
• Johnston GD. Dose-response relationships with antihypertensive drugs. Clin Pharmacol Ther 1992; 55: 53–93
  CAS Google Scholar
• Corea L, Cardoni O, Fogari R, et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996; 60: 341–6
  Article PubMed CAS Google Scholar
• Salvetti A, Arzilli F. Chronic dose-response curve of enalapril in essential hypertensives. An Italian multicenter study. Am J Hypertens 1989; 2: 352–4
  PubMed CAS Google Scholar
• Gomez HJ, Cirillo VJ, Sromovsky JA, et al. Lisinopril dose-response relationship in essential hypertension. Br J Clin Pharmacol 1989; 28: 415–20
  Article PubMed CAS Google Scholar
• Anderson RJ, Duchin KL, Gore RD, et al. Once-daily fosinopril in the treatment of hypertension. Hypertension 1991; 17: 636–42
  Article PubMed CAS Google Scholar
• Pool JL. Antihypertensive effect of fosinopril, a new angiotensin converting enzyme inhibitor: findings of the fosinopril study group II. Clin Ther 1990; 12: 520–33
  PubMed CAS Google Scholar
• Chrysant SG, McDonald RH, Wright JT, et al. Perindopril as monotherapy in hypertension: a multicenter comparison of two dosing regimens. Clin Pharmacol Ther 1993; 53: 479–84
  Article PubMed CAS Google Scholar
• Drayer JM, Stimpel M, Fox A, et al. The antihypertensive properties of the angiotensin converting enzyme inhibitor moexipril given alone or in combination with a low dose of a diuretic. Am J Ther 1995; 2: 525–31
  Article PubMed Google Scholar
• Vandenburg MJ, Mackay EM, Dews I, et al. Dose finding studies with imidapril-a new ACE inhibitor. Br J Clin Pharmacol 1994; 37: 265–72
  Article PubMed CAS Google Scholar
• Sedman AJ, Posvar E. Clinical pharmacology of quinapril in healthy volunteers and in patients with hypertension and congestive heart failure. Angiology 1989; 40: 360–9
  PubMed CAS Google Scholar
• Weinberger MH, Black HR, Lasseter KC, et al. Diurnal blood pressure in patients with mild-to-moderate hypertension treated with once-daily benazepril. Clin Pharmacol Ther 1990; 47: 608–17
  Article PubMed CAS Google Scholar
• Guyenne TT, Bellet M, Sassano P, et al. Crossover design for the dose determination of an angiotensin converting enzyme inhibitor in hypertension. J Hypertens 1989; 7: 1005–12
  Article Google Scholar
• Bellet M, Whalen JJ, Bodin F, et al. Use of crossover trials to obtain antihypertensive dose-response curves and to study combination therapy during the development of benazepril. J Hypertens 1990; 8 Suppl. 4: S43–8
  CAS Google Scholar
• Meredith PA, Elliott HL. FDA guidelines on trough: peak ratios in the evaluation of antihypertensive agents. J Cardiovasc Pharmacol 1994; 23 Suppl. 5: S26–30
  Article PubMed CAS Google Scholar
• Zannad F, Matzinger A, Larche J. Trough/peak ratios of once-daily angiotensin converting enzyme inhibitors and calcium antagonists. Am J Hypertens 1996; 9: 633–43
  Article PubMed CAS Google Scholar
• Staessen JA, Thijs L, Bijttebier G, et al. Determining the trough-to-peak ratio in parallel-group trials. Hypertension 1997; 29: 659–67
  Article PubMed CAS Google Scholar